129 related articles for article (PubMed ID: 28866246)
61. [Conservative therapy by percutaneous radiofrequency ablation of renal cell carcinomas--therapeutic experiments of four patients with seven renal tumors--].
Karashima T; Inoue K; Shimamoto T; Yamasaki I; Kamada M; Shuin T
Hinyokika Kiyo; 2006 Apr; 52(4):241-7. PubMed ID: 16686349
[TBL] [Abstract][Full Text] [Related]
62. Oncologic outcomes using real-time peripheral thermometry-guided radiofrequency ablation of small renal masses.
Leveillee RJ; Castle SM; Gorbatiy V; Salas N; Narayanan G; Morillo-Burgos G; Jorda M; Faraday MM
J Endourol; 2013 Apr; 27(4):480-9. PubMed ID: 23098088
[TBL] [Abstract][Full Text] [Related]
63. Long-term oncologic outcomes following radiofrequency ablation with real-time temperature monitoring for T1a renal cell cancer.
Lorber G; Glamore M; Doshi M; Jorda M; Morillo-Burgos G; Leveillee RJ
Urol Oncol; 2014 Oct; 32(7):1017-23. PubMed ID: 24996776
[TBL] [Abstract][Full Text] [Related]
64. Low-dose CT protocols for guiding radiofrequency ablation for the treatment of small renal cell carcinomas.
Park BK
Int J Hyperthermia; 2018 Sep; 34(6):877-882. PubMed ID: 28847190
[TBL] [Abstract][Full Text] [Related]
65. Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease.
Phillips JL; Ghadimi BM; Wangsa D; Padilla-Nash H; Worrell R; Hewitt S; Walther M; Linehan WM; Klausner RD; Ried T
Genes Chromosomes Cancer; 2001 May; 31(1):1-9. PubMed ID: 11284029
[TBL] [Abstract][Full Text] [Related]
66. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
67. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.
Mukhopadhyay D; Knebelmann B; Cohen HT; Ananth S; Sukhatme VP
Mol Cell Biol; 1997 Sep; 17(9):5629-39. PubMed ID: 9271438
[TBL] [Abstract][Full Text] [Related]
68. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
69. Cancer-free survival and local tumor control after impendence-based radiofrequency ablation of biopsy-proven renal cell carcinomas with a minimum of 1-year follow-up.
Forauer AR; Dewey BJ; Seigne JD
Urol Oncol; 2014 Aug; 32(6):869-76. PubMed ID: 24946958
[TBL] [Abstract][Full Text] [Related]
70. Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study.
Schouten LJ; van Dijk BA; Oosterwijk E; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Schalken JA; van den Brandt PA
J Hypertens; 2005 Nov; 23(11):1997-2004. PubMed ID: 16208141
[TBL] [Abstract][Full Text] [Related]
71. Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study.
Chanez B; Caillol F; Ratone JP; Pesenti C; Rochigneux P; Pignot G; Thomassin J; Brunelle S; Walz J; Salem N; Giovannini M; Gravis G
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771431
[TBL] [Abstract][Full Text] [Related]
72. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.
Rahma OE; Ashtar E; Ibrahim R; Toubaji A; Gause B; Herrin VE; Linehan WM; Steinberg SM; Grollman F; Grimes G; Bernstein SA; Berzofsky JA; Khleif SN
J Transl Med; 2010 Jan; 8():8. PubMed ID: 20109232
[TBL] [Abstract][Full Text] [Related]
73. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
[TBL] [Abstract][Full Text] [Related]
74. Retroperitoneoscopic-guided radiofrequency ablation of renal tumors.
Pautler SE; Pavlovich CP; Mikityansky I; Drachenberg DE; Choyke PL; Linehan WM; Wood BJ; Walther MM
Can J Urol; 2001 Aug; 8(4):1330-3. PubMed ID: 11564277
[TBL] [Abstract][Full Text] [Related]
75. Renal involvement in von Hippel-Lindau disease.
Chauveau D; Duvic C; Chrétien Y; Paraf F; Droz D; Melki P; Hélénon O; Richard S; Grünfeld JP
Kidney Int; 1996 Sep; 50(3):944-51. PubMed ID: 8872970
[TBL] [Abstract][Full Text] [Related]
76. Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours.
Ma Y; Bedir S; Cadeddu JA; Gahan JC
BJU Int; 2014 Jan; 113(1):51-5. PubMed ID: 24053553
[TBL] [Abstract][Full Text] [Related]
77. Percutaneous ultrasound-guided radiofrequency ablation of an allograft renal cell carcinoma: a case report.
Olivani A; Iaria M; Missale G; Capocasale E; Biasini E; Mazzoni MP; Lombardelli L; Luzi E; Frattini A; Pelosi G
Transplant Proc; 2011 Dec; 43(10):3997-9. PubMed ID: 22172886
[TBL] [Abstract][Full Text] [Related]
78. Laparoscopic radiofrequency ablation with intraoperative contrast-enhanced ultrasonography for T1bN0M0 renal tumors: initial functional and oncologic outcomes.
Yang R; Lian H; Zhang G; Wang W; Gan W; Li X; Yan X; Zhang S; Zhao X; Guo H
J Endourol; 2014 Jan; 28(1):4-9. PubMed ID: 23998802
[TBL] [Abstract][Full Text] [Related]
79. [Tumor size and DNA ploidy changes in renal cell carcinomas--flow cytometric analysis of DNA content in renal cell carcinomas associated with von Hippel-Lindau disease].
Nagamori S; Shinohara N; Kashiwagi A; Togashi M; Seki H; Toyota K; Harabayashi T; Nonomura K; Koyanagi T
Nihon Hinyokika Gakkai Zasshi; 1996 Apr; 87(4):754-9. PubMed ID: 8691697
[TBL] [Abstract][Full Text] [Related]
80. Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience.
Gonnet A; Salabert L; Roubaud G; Catena V; Brouste V; Buy X; Gross Goupil M; Ravaud A; Palussière J
BMC Cancer; 2019 Dec; 19(1):1182. PubMed ID: 31795959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
